Peer Review History
| Original SubmissionMarch 13, 2021 |
|---|
|
PONE-D-21-08313 Management of common minor ailments in Qatar: Community pharmacists’ self-perceived competency and its predictors PLOS ONE Dear Dr. Yusuff, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Jenny Wilkinson, PhD Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. Moreover, please include more details on how the questionnaire was pre-tested, and whether it was validated. 3. Please correct your reference to "p=0.000" to "p<0.001" or as similarly appropriate, as p values cannot equal zero. Additional Editor Comments: Thank you for your submission. The reviewers have provided comments and suggests to strengthen your work and provide readers with a better understanding of both the methods used and the interpretation and context of your findings. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: 1) Some grammatical mistakes, like Line 85, where is should read "The literature search ...". Others like this were evident throughout, which I did not focus on here. The big issues will be first ... 2) The conglomeration of numbers to arrive at 1260 and 1290 can be figured out by readers, but I don't think I would call it intuitive. Also, the only mention of this global score was at Line 254, however one can assume the numbers in Table 3 would accrue up to that value. Either way, given the attention it got in the Methods, it got very little attention in the Results. That makes understanding Table 3 pretty tricky. 3) In Lines 167-168, which items of the "final questionnaire" were included in the Cronbach's alpha measure? If it included such things as the Demographics, then we have a problem (those items would not be "internally consistent" with other items). IF the 12 items of competence were the source, then there is some hope. That said, however, you have 12 quite diverse items in that list, and the question is -- are they truly all ONE construct that can actually have internal consistency? Either way, later in Line 345, you simply CANNOT say you attained a "valid and reliable" survey based on that score alone. Even with the input from 3 faculty and 1 practitioner for content validity, you have to tone down your choice of words here. Regarding reliability, authors often confuse "reliability" of Cronbach's alpha with actual test-retest reliability, where a second measure is taken to see if its reliable over time. 4) Not enough attention is devoted to the 1-10 Likert Scale. All we know are the poles -- LOW and FULL. What about the other 8 points on the scale? Did you use any verbal descriptors? 5) A critical limitation of all survey research is trying to distill complex attitudes/beliefs down to numbers (as in, a scale of some sort). Using a scale to measure competence has to be recognized as a Limitation. 6) On Line 337, you claim you have 'added significantly' to the field. Its good to be optimistic, but we often don't reach that level. I would be more introspect. 7) I think the editors should have a statistician check out Table 5, to make sure all is on solid ground. 8) Related to the 1-10 scale, you went with them being ordinal rather than interval. Many do that. Many others go with intervality, thus jumping to means. That explains the use of Medians for your Results. Just a comment, no changes suggested. However, I would wonder whether mean years of practice would be better than IQR (Line 207). 9) For Lines 208-211, with at least 30 encounters occurring per shift, I was surprised to see 11-30 being the number for minor ailments. That means most in a day were of this sort. Just an observation. 10) Regarding how the list of Minor Ailments was created, I can live with the references cited (17-19,27-31), except that refs 19 and 31 seem like outliers here (just one condition each -- VGE and headache). In your approach, you could have taken to how others have defined Minor Ailments, which then leads to a list of possible candidates (as would have been described in ref 27). As an aside, I found it odd that acne, warts, diarrhea, cold sores, heartburn did not surface. But, you get what you get. Of note, Athlete Foot should read Athlete's Foot. 11) For the sample size calculation, I agree with the method. However, one should note that the "response distribution of 50%" literally refers to surveys where only a FOR/AGAINST option is available. That is, a 50/50 proposition for a response. In your case, you would not have such a set-up. That stated, no changes suggested here. 12) For Lines 169-176, it is tricky to follow the 12 competency elements -- 9 condition and 3 non-condition. Table 3 lists out the 9, fine. At Lines 159-161, the non-condition ones are listed. Thereafter for those 3, only special populations appears (Line 281). The others are basically ignored. Furthermore, I think you have 4 of those, not 3 -- Documentation and Use of Resources are clearly separate things. 13) I am not sure you found all the key reports to cite: a) Stewart IJPP 2009, 17: 89-94, b) George Ann Pharmaco 2006, 40: 1843-50, c) Hoti Pharm World Sci 2010, 32: 610-21, d) Taylor SelfCare 2016, 7(1): 10-21 ... might be of some use. 14) In Table 1, the Experience line, you have "(years)", "(IQR)", but also "(%)" at the top of the column, making it hard to understand the listing of "7 (4, 10.3)". 15) In Table 3, I think you have some unintended consequences. "Description/Definition" could easily overlap with "Signs and Symptoms". 16) Lines 313-314 -- I don't think you want to qualify the data here with use of "notwithstanding". The lower numbers of women is not an issue here, you simply mention the discrepancy seen, which stands on its own. Reviewer #2: Many thanks for the opportunity to review this manuscript investigating the self-efficacy or self-perception of competency in managing minor ailments in pharmacies in Qatar. I am not convinced of the need for and the contribution of this work. I describe some observations below to illustrate this concern. From the outset of the manuscript, the size or real extent of the problem that the findings of this study aim to address is not entirely convincing. Is it a case in Qatar that minor ailments are being referred inappropriately out of pharmacy and therefore contributing the burden in ED and GPs? In the discussion, it is presented that self-efficacy was generally high and authors comment that this has the potential to relieve the burden from elsewhere in the system. I would contest that based on the core training of pharmacists globally, there is an acknowledgement and expectation that pharmacists can manage minor ailments, so this study has not really addressed or answered a pressing issue or question. In fact it is in most cases, the structure of the healthcare systems, health-seeking behaviours of the population and resource accessibility in community pharmacy that lead to overburdened ED and primary care physicians being consulted for minor ailments. Pharmacists are not conventionally diagnosticians (therefore unsurprising that ability to differentiate minor ailment from other conditions was the lowest rated competency score), therefore the management of minor ailments has always been on the premise of management of symptoms and escalation/referral where 'red flags' or problems fall outside of the competence of a pharmacist. Therefore, when minor ailments are referred to, there needs to be a description about the nature and acuity of that ailment. Asking a pharmacist whether they can manage constipation is ambiguous if there are no other details about the patient and the ailment, e.g. how long experienced the symptoms, recent travel abroad, with other symptoms, etc. So if a pharmacist rates themselves as less confident/competent, are they really rating themselves on what the researcher thinks or are they thinking about the unknowns surrounding that condition? In brief, what does the quantitative analysis of pharmacist's self-efficacy really tell us? They are risk averse? They are not comfortable with the ambiguity in the questions? There are deficiencies in the training of that pharmacist? The authors suggest that there is a competency gap due to the lower score on the ability to undertake differential diagnoses. I think this assumption does not acknowledge the generally low access of community pharmacists to patient clinical records that would facilitate clinical and therapeutic reasoning. So is it all about competency? The implications for policy and practice are overly simplified. The understanding of self-perceived competency is not sufficient information on which to build a national strategy/framework for managing minor ailments. There needs to be acknowledgement that minor ailments exist on a continuum of acuity, and it is about understanding what community pharmacists can do to contribute to the overall load. Shifting all patients with constipation to community pharmacy may not be the most safe and appropriate recommendation simply based on these findings. Which types of patients? What grades of constipation? What are the thresholds for referrals? These are going to be really important to build a framework. It is worth reflecting on whether self-efficacy equates to safer, more effective practice and outcomes. Because females are more confident, is the assumption they are best placed to manage minor ailments in community pharmacy? I think this needs some more consideration. Similarly, it would be interesting to investigate why those in chain pharmacies feel more confident, and if their performance in managing minor ailments is indeed better. So the findings of this work offer further areas to investigate before being very helpful in informing the deign of an intervention/framework. Some other more specific comments: The first few lines of the abstract are overly convoluted and could be expressed much simpler. What is the problem that this study aims to address/investigate? Introduction Lines 87-98 I appreciate that the authors have linked the aim of this study to Bandura's SCT in order to justify measuring self-competency. However, the link and significance to practice is not entirely convincing. Was content validity really assessed? If so, how was this done? And the results need to be included. Or was it face validity? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-21-08313R1 Management of common minor ailments in Qatar: Community pharmacists’ self-perceived competency and its predictors PLOS ONE Dear Dr. Yusuff, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 09 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Jenny Wilkinson, PhD Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Thank you for your revisions. Some additional comments are provided for your consideration. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I am fine with the corrections made, except for the following: I would advise against the approach you took in your rebuttal to reviewer comments. On several instances, the feeling appeared to be 'while we thank the reviewer for the comment, we did it the right way' and will disregard it. For example, regarding the Likert scale sequence, it will not suffice to say that responders were 'given detailed instructions' and things were successful. Likert scales are very tricky devices, and to ask for input into what came b/n Low and Full was a reasonable request to make. Secondly, to state that Description and Signs/Symptoms were sufficiently distinct items, I would love to be enlightened. When I think of the Description of the Common Cold, I conjure up "a viral upper respiratory infection manifesting as nasal congestion, runny nose, perhaps a cough, maybe a headache etc. Now, how do signs/symptoms deviate from that? For line 346, the statement -- "probably suggests the study findings are valid and reliable" -- based on a sole Cronbach's alpha is too far-reaching. I like your items in Table 3. Regardless of that stance, do you really feel you got things so right in the survey to make that conclusion?? I look back to all the OTC research I have done over 30 years and I STILL worry about what mistakes I made. There are many others, but I will let it rest. Lastly, to downgrade "significantly add to the literature" to "may significantly add" is still clearly over-valuing the work you created. It is just not that profound, similar to the rest of us working in this area. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Management of common minor ailments in Qatar: Community pharmacists’ self-perceived competency and its predictors PONE-D-21-08313R2 Dear Dr. Yusuff, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Jenny Wilkinson, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): Thank you for your responses, these have addressed the reviewer comments Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-08313R2 Management of common minor ailments in Qatar: Community pharmacists’ self-perceived competency and its predictors Dear Dr. Yusuff: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr Jenny Wilkinson Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .